AT2 receptor agonists: Exploiting the beneficial Arm of Ang II signaling

Current Hypertension Reviews

Volumn 8, Issue 1, 2012, Pages 47-59

  Gallo Payet, Nicole ^a   Shum, Michael ^a   Baillargeon, Jean Patrice ^a   Langlois, Marie France ^a   Wallinder, Charlotta ^b   Alterman, Mathias ^b   Hallberg, Anders ^b   Carpentier, André C ^a  

^a Centre Hospitalier Universitaire de Sherbrooke   (Canada)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Adipocyte; Angiotensin II; Angiotensin type 1 receptor; Angiotensin type 2 receptor; Differentiation; Insulin resistance

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN II; CYTOKINE; HORMONE RECEPTOR STIMULATING AGENT; L 162 313; LOSARTAN; M24 COMPOUND; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; NOVOKININ; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG EFFECT; ENERGY BALANCE; ENERGY EXPENDITURE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIGAND BINDING; METABOLIC DISORDER; NERVE FIBER GROWTH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 84870174842     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340212800504990     Document Type: Review

References (205)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
2. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90: 449-55.
3. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287: H435-H46.
4. Millan MA, Jacobowitz DM, Aguilera G, Catt KJ. Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA 1991; 88: 11440-4.
5. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261: R209-R16.
6. Schutz S, Le Moullec JM, Corvol P, Gasc JM. Early expression of all the components of the renin-angiotensin-system in human development. Am J Pathol 1996; 149: 2067-79.
7. Breault L, Lehoux JG, Gallo-Payet N. The angiotensin AT2 receptor is present in the human fetal adrenal gland throughout the second trimester of gestation. J Clin Endocrinol Metab 1996; 81: 3914-22.
8. Guillon G, Trueba M, Joubert D, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology 1995; 136: 1285-95.
9. Johnson M, Vega M, Vantman D, Troncoso J, Devoto L. Regulatory role of angiotensin II on progesterone production by cultured human granulosa cells. Expression of angiotensin II type-2 receptor. Mol Hum Reprod 1997; 3: 663-8.
10. Pucell A, Hodges J, Sen I, Bumpus F, Husain A. Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology 1991; 128: 1947-59.
11. Yoshimura Y, Karube M, Aoki H, et al. Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Endocrinology 1996; 137: 1204-11.
12. Chiu A, Herblin W, McCall D, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 165: 196-203.
13. Speth R, Kim K. Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, paminophenylalanine6 angiotensin II. Biochem Biophys Res Commun 1990; 169: 997-1006.
14. Speth R, Mei L, Yamamura H. Angiotensin II receptor binding and actions in NG108-15 cells. Pept Res 1989; 2: 232-9.
15. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163: 284-91.
16. Yamada H, Akishita M, Ito M, et al. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 1999; 33: 1414-9.
17. Lenkei Z, Palkovits M, Corvol P, Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 1997; 18: 383-439.
18. Yu L, Zheng M, Wang W, Rozanski GJ, Zucker IH, Gao L. Developmental changes in AT1 and AT2 receptor-protein expression in rats. J Renin Angiotensin Aldosterone Syst 2010; 11: 214-21.
19. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
20. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003; 21: 1429-43.
21. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 2003; 140: 809-924.
22. Steckelings UM, Rompe F, Kaschina E, et al. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst 2010; 11: 67-73.
23. Carey RM. Angiotensin type-2 receptors and cardiovascular function: are angiotensin type-2 receptors protective? Curr Opin Cardiol 2005; 20: 264-9.
24. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007; 49: 341-6.
25. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst 2009; 11: 33-6.
26. Unger T. Targeting Cardiovascular Protection: The Concept of Dual Renin-Angiotensin System Control. Medscape J Med 2008; 10(Supp): S4-S11.
27. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11: 19-31.
28. Horiuchi M, Mogi M, Iwai M. The angiotensin II type 2 receptor in the brain. J Renin Angiotensin Aldosterone Syst 2010; 11: 1-6.
29. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-9.
30. Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008; 15: 19-26.
31. Chow L, Rezmann L, Catt KJ, et al. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol 2009; 302: 219-29
32. Reudelhuber TL. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005; 46: 1261-2.
33. Porrello ER, Delbridge LM, Thomas WG. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci 2009; 14: 958-72.
34. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003; 4: 43-55.
35. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-6.
36. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-73.
37. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293: R974-R80.
38. Goossens GH, Blaak EE, Arner P, Saris WH, van Baak MA. Angiotensin II: a hormone that affects lipid metabolism in adipose tissue. Int J Obes (Lond) 2007; 31: 382-4.
39. Muscogiuri G, Chavez AO, Gastaldelli A, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 2008; 6: 301-12.
40. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Reninangiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26: 831-43.
41. Lenz O, Fornoni A Renin-angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center. Kidney Int 2008; 74: 851-3.
42. Ribeiro-Oliveira A, Jr., Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 2008; 4: 787-803.
43. Iwai M, Horiuchi M. Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res 2009; 32: 425-7.
44. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128-39.
45. de Kloet AD, Krause EG, Woods SC The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100: 525-34.
46. Abuissa H, Jones PG, Marso SP, O'Keefe JH, Jr. Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-6.
47. Unger T, Stoppelhaar M. Rationale for double renin-angiotensinaldosterone system blockade. Am J Cardiol 2007; 100: 25J-31J.
48. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.
49. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.
50. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004; 30: 498-505.
51. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in strokeprone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 2006; 24: 2417-22.
52. Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 2008; 97: 418-31.
53. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-56.
54. Horiuchi M, Mogi M, Iwai M. Signaling crosstalk angiotensin II receptor subtypes and insulin. Endocr J 2006; 53: 1-5.
55. Mogi M, Horiuchi M. Effects of angiotensin II receptor blockers on dementia. Hypertens Res 2009; 32: 738-40.
56. van de Wal RM, van der Harst P, Wagenaar LJ, et al. Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. J Cardiovasc Pharmacol 2007; 50: 372-9.
57. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH. Functional interaction of AT1 and AT2 receptors in fructoseinduced insulin resistance and hypertension in rats. Metabolism 2005; 54: 157-64.
58. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33: 1237-42.
59. Hakam AC, Hussain T. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 2005; 45: 270-5.
60. Gendron L, Payet M, Gallo-Payet N. The AT2 receptor of angiotensin II and neuronal differentiation: From observations to mechanisms. J Mol Endocrinol 2003; 31: 359-72.
61. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 1994; 35: 1378-85.
62. Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999; 140: 154-8.
63. Schling P. Expression of angiotensin II receptors type 1 and type 2 in human preadipose cells during differentiation. Horm Metab Res 2002; 34: 709-15.
64. Weiland F, Verspohl EJ Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 2008; 40: 760-6.
65. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-8.
66. Ye Z, Wu X, Jiang J. Expression changes of angiotensin II pathways and bioactive mediators during human preadipocytesvisceral differentiation. Metabolism Clin and Exp 2009; 58: 1288-96.
67. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512-9.
68. Safonova I, Aubert J, Negrel R, Ailhaud G. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J 1997; 322 235-9.
69. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287: E227-E32.
70. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgammaactivating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-43.
71. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensinaldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16: 120-6.
72. Rajala MW, Scherer PE. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-73.
73. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14 Suppl 5: 242S-9S.
74. Scherer PE Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-45.
75. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-53.
76. Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007; 48: 1253-62.
77. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007; 21: 1443-55.
78. Anghel SI, Bedu E, Vivier CD, Descombes P, Desvergne B, Wahli W Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma. J Biol Chem 2007; 282: 29946-57.
79. Carpentier A. Postprandial fatty-acid metabolism in the development of lipotoxicity and type 2 diabetes. Diabetes & Metabolism 2008; 34: 97-107.
80. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-77.
81. Tan CY, Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans 2008; 36: 935-40.
82. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 2006; 15: 173-8.
83. Garbarino J, Sturley SL. Saturated with fat: new perspectives on lipotoxicity. Curr Opin Clin Nutr Metab Care 2009; 12: 110-1166.
84. Gray SL, Vidal-Puig AJ. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 2007; 65: S7-S12.
85. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. Biochim Biophys Acta 2010; 1801: 338-49.
86. Arner E, Westermark PO, Spalding KL, et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 2010; 59: 105-9.
87. Granneman JG, Moore HP, Granneman RL, Greenberg AS, Obin MS, Zhu Z. Analysis of lipolytic protein trafficking and interactions in adipocytes. J Biol Chem 2007; 282: 5726-35.
88. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006; 7: 885-96.
89. Bost F, Aouadi M, Caron L, et al. The extracellular signalregulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005; 54: 402-11.
90. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131: 242-56.
91. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-9.
92. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-11.
93. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006; 48: 1095-102.
94. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004; 13: 325-32.
95. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004; 145: 169-74.
96. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001; 142: 487-92.
97. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001; 37: 1336-40.
98. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 2004; 24: 1199-203.
99. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 2005; 13: 969-73.
100. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K. Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005; 48: 1066-74.
101. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84.
102. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007; 292: E166-E74.
103. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-12.
104. Mori Y, Itoh Y, Tajima N Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007; 20: 431-6.
105. Iwai M, Tomono Y, Inaba S, Kanno H, Senba I, Mogi M, Horiuchi M. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens 2009; 22: 784-91.
106. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54: 991-9.
107. Yvan-Charvet L, Even P, Lamande N, Ferre P, Quignard-Boulange A. Prevention of Adipose Tissue Depletion during Food Deprivation in Angiotensin Type 2 Receptor-Deficient Mice. Endocrinology 2006; 147: 5078-86.
108. Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 2011; 79: 162-8.
109. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-10.
110. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the reninangiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-82.
111. Di Filippo C, Lampa E, Tufariello E, et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res 2005; 13: 1909-14.
112. Zorad S, Dou JT, Benicky J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006; 552: 112-22.
113. Lee MH, Song HK, Ko GJ, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890-900.
114. Siddiqui AH, Ali Q, Hussain T. Protective Role of Angiotensin II Subtype 2 Receptor in Blood Pressure Increase in Obese Zucker Rats. Hypertension 2009; 53: 256-61.
115. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-86.
116. Munoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 2009; 27: 2409-20.
117. Tian F, Luo R, Zhao Z, Wu Y, Ban D. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2009; 118: 258-65.
118. Furuhashi M, Ura N, Nakata T, Shimamoto K. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care 2003; 26: 471-4.
119. Funke-Kaiser H, Reinemund J, Steckelings UM, Unger T. Adapter proteins and promoter regulation of the angiotensin II type 2 receptor-implications for cardiac pathophysiology. J Renin Angiotensin Aldosterone Syst 2010; 11: 7-17.
120. McLaughlin T, Deng A, Yee G, et al. Inflammation in subcutaneous adipose tissue: relationship to adipose cell size. Diabetologia 2009; 53: 369-77.
121. McLaughlin T, Sherman A, Tsao P, et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 2007; 50: 1707-15.
122. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9.
123. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7.
124. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
125. Piche ME, Lapointe A, Weisnagel SJ, et al. Regional body fat distribution and metabolic profile in postmenopausal women. Metabolism 2008; 57: 1101-7.
126. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 2010; 34: 949-59.
127. Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol 1998; 275: H1395-H403.
128. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999; 10 Suppl 11: S149-S61.
129. Boschmann M, Ringel J, Klaus S, Sharma AM. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001; 9: 486-91.
130. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322-9.
131. Zhou J, Pavel J, Macova M, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37: 1271-6.
132. Brillante DG, O'Sullivan AJ, Johnstone MT, Howes LG. Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes Obes Metab 2008; 10: 143-50.
133. Fujita T, Mogi M, Min LJ, et al. Attenuation of cuff-induced neointimal formation by overexpression of angiotensin II type 2 receptor-interacting protein 1. Hypertension 2009; 53: 688-93.
134. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides 2005; 26: 1401-9.
135. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31: 349-55.
136. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptorblocked rats. Hypertension 2001; 38: 1272-7.
137. Dimitropoulou C, White RE, Fuchs L, Zhang H, Catravas JD, Carrier GO. Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca) channels. Hypertension 2001; 37: 301-7.
138. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptormediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40: 516-20.
139. Tanaka M, Tsuchida S, Imai T, et al. Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. Biochem Biophys Res Commun 1999; 258: 194-8.
140. Gigante B, Rubattu S, Russo R, et al. Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension 1997; 30: 563-8.
141. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke. Stroke 2009; 40: 1482-9.
142. Ohinata K, Fujiwara Y, Fukumoto S, Iwai M, Horiuchi M, Yoshikawa M. Angiotensin II and III suppress food intake via angiotensin AT(2) receptor and prostaglandin EP(4) receptor in mice. FEBS Lett 2008; 582: 773-7.
143. Ohinata K, Fujiwata Y, Shingo F, Masaru I, Masatsugu H, Yoshikawa M. Orally administered novokinin, an angiotensin AT2 receptor agonist, suppresses food intake via prostaglandin E2-dependent mechanism in mice. Peptides 2009; 30: 1105-8.
144. Martineau D, Lamouche S, Briand R, Yamaguchi N. Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo. Can J Physiol Pharmacol 1999; 77: 367-74.
145. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266-72.
146. Fabiani ME, Sourial M, Thomas WG, Johnston CI, Frauman AG. Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia. J Endocrinol 2001; 171: 97-108.
147. Roulston CL, Lawrence AJ, Jarrott B, Widdop RE. Nonangiotensin II [(125)I] CGP42112 binding is a sensitive marker of neuronal injury in brainstem following unilateral nodose ganglionectomy: comparison with markers for activated microglia. Neuroscience 2004; 127: 753-67.
148. Steckelings UM, Larhed M, Hallberg A, et al. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2010; 11: 1-6.
149. Unger T, Dahlof B. Compound 21, the first orally active, selective agonist of the angiotensin II type 2 (AT2) receptor: implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 2010; 11: 75-7.
150. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47: 5995-6008.
151. Wu X, Wan Y, Mahalingam AK, Murugaiah AM, et al. Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships. J Med Chem 2006; 49: 7160-8.
152. Georgsson J, Skold C, Plouffe B, et al. Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity. J Med Chem 2005; 48: 6620-31.
153. Rosenstrom U, Skold C, Plouffe B, et al. New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists. J Med Chem 2005; 48: 4009-24.
154. Georgsson J, Rosenstrom U, Wallinder C, et al. Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity. Bioorg Med Chem 2006; 14: 5963-72.
155. Murugaiah AM, Wallinder C, Mahalingam AK, et al. Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system. Bioorg Med Chem 2007; 15: 7166-83.
156. Georgsson J, Skold C, Botros M, et al. Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor. J Med Chem 2007; 50: 1711-5.
157. Gelosa P, Pignieri A, Fändriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009; [Epub ahead of print].
158. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the nonpeptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159: 709-16.
159. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2009; 118: 2523-32.
160. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010; 55: 924-31.
161. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens 1999; 17: 1775-17786.
162. Siragy HM, Xue C, Abadir P, Carey RM. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005; 45: 133-7.
163. Gendron L, Laflamme L, Rivard N, Asselin C, Payet M, Gallo-Payet N. Signals from the AT2 receptor of angiotensin II inhibit p21ras and activate MAPK to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13: 1615-26.
164. Beaudry H, Gendron L, Guimond MO, Payet MD, Gallo-Payet N. Involvement of protein kinase C alpha (PKC alpha) in the early action of angiotensin II type 2 (AT2) effects on neurite outgrowth in NG108-15 cells: AT2-receptor inhibits PKC alpha and p21ras activity. Endocrinology 2006; 147: 4263-72.
165. Gendron L, Oligny JF, Payet MD, Gallo-Payet N. Cyclic AMPindependent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem 2003; 278: 3606-14.
166. Stroth U, Blume A, Mielke K, Unger T Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res Mol Brain Res 2000; 78: 175-80.
167. Plouffe B, Guimond MO, Beaudry H, Gallo-Payet N. Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells. Endocrinology 2006; 147: 4646-54.
168. Guimond MO, Roberge C, Gallo-Payet N. Fyn is involved in angiotensin II type 2 receptor-induced neurite outgrowth, but not in p42/p44mapk in NG108-15 cells. Mol Cell Neurosci 2010; 45: 201-12.
169. Côté M, Muyldermans J, Chouinard L, Gallo-Payet N. Involvement of tyrosine phosphorylation and MAPK activation in the mechanism of action of ACTH, angiotensin II and vasopressin. Endocr Res. 1998; 24: 415-9.
170. Gendron L, Côté F, Payet M, Gallo-Payet N. Nitric oxide and cyclic GMP are involved in angiotensin II AT2 receptor effects on neurite outgrowth in NG108-15 cells. Neuroendocrinology 2002; 75: 70-81.
171. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996; 97: 1978-82.
172. Searles CD, Harrison DG. The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest 1999; 104: 1013-4.
173. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006; 48: 316-22.
174. Nouet S, Amzallag N, Li JM, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004; 279: 28989-97.
175. Li JM, Mogi M, Tsukuda K, et al. Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol Endocrinol 2007; 21: 499-511.
176. Zhao Y, Foryst-Ludwig A, Bruemmer D, Culman J, Bader M, Unger T, Kintscher U. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem 2005; 94: 1395-401.
177. Mogi M, Li JM, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446-9.
178. Tsuzuki S, Eguchi S, Inagami T. Inhibition of cell proliferation and activation of protein tyrosine phosphatase mediated by angiotensin II type 2 (AT2) receptor in R3T3 cells. Biochem Biophys Res Commun 1996; 228: 825-30.
179. Shibasaki Y, Matsubara H, Nozawa Y, et al. Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase. Hypertension 2001; 38: 367-72.
180. Elbaz N, Bedecs K, Masson M, Sutren M, Strosberg AD, Nahmias C. Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. Mol Endocrinol 2000; 14: 795-804.
181. Cui T, Nakagami H, Iwai M, et al. Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc Res 2001; 49: 863-71.
182. Di Benedetto M, Bieche I, Deshayes F, et al. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene 2006; 380: 127-36.
183. Wruck CJ, Funke-Kaiser H, Pufe T, et al. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol 2005; 25: 57-64.
184. Feng YH, Sun Y, Douglas JG. Gbeta gamma-independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1. Proc Natl Acad Sci U S A 2002; 99: 12049-54.
185. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-9.
186. Mogi M, Li JM, Iwanami J, et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-8.
187. Otto TC, Lane MD Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol 2005; 40: 229-42.
188. Yeyati PL, Shaknovich R, Boterashvili S, et al. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18: 925-34.
189. Costoya JA, Hobbs RM, Pandolfi PP. Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation. Oncogene 2008; 27: 3789-96.
190. Kang SI, Chang WJ, Cho SG, Kim IY. Modification of promyelocytic leukemia zinc finger protein (PLZF) by SUMO-1 conjugation regulates its transcriptional repressor activity. J Biol Chem 2003; 278: 51479-83.
191. Ko JH, Son W, Bae GY, Kang JH, Oh W, Yoo OJ. A new hepatocytic isoform of PLZF lacking the BTB domain interacts with ATP7B, the Wilson disease protein, and positively regulates ERK signal transduction. J Cell Biochem 2006; 99: 719-34.
192. Senbonmatsu T, Ichihara S, Price E, Jr., Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 2000; 106: R1-R5.
193. Senbonmatsu T, Saito T, Landon EJ, et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. Embo J 2003; 22: 6471-82.
194. Wu L, Iwai M, Li Z, et al. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol 2004; 18: 666-78.
195. Stegbauer J, Coffman TM. New insights into angiotensin receptor actions: from blood pressure to aging. Curr Opin Nephrol Hypertens 2011; 20: 84-8.
196. Matavelli LC, Huang J, Siragy HM. Angiotensin AT receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 2011; 57: 308-13.
197. Sabuhi R, Ali Q, Asghar M, Al-Zamily NR, Hussain T. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol 2011; 300: F700-F6.
198. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
199. Juan CC, Chien Y, Wu LY, et al. Angiotensin II enhances insulin sensitivity in vitro and in vivo. Endocrinology 2005; 146: 2246-54.
200. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-9.
201. Arellano-Plancarte A, Hernandez-Aranda J, Catt KJ, Olivares-Reyes JA. Angiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells. Biochem Pharmacol 2010; 79: 733-45.
202. Cui TX, Nakagami H, Nahmias C, et al. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol 2002; 16: 2113-23.
203. Morisco C, Lembo G, Trimarco B. Insulin resistance and cardiovascular risk: New insights from molecular and cellular biology. Trends Cardiovasc Med 2006; 16: 183-8.
204. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 2007; 27: 2532-9.
205. Tsukuda K, Mogi M, Li JM, et al. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50: 1099-105.